This $1,004,107 Project Grant award from the National Cancer Institute's Cancer Detection and Diagnosis Research program (CFDA 93.394) supports the development and clinical validation of Precision Epigenomics Inc.'s Sentinel-MPE liquid biopsy assay. The Sentinel-MPE test aims to improve the diagnosis of malignant pleural effusions, which are a challenging clinical issue. The key product of this 2-year project is to establish the diagnostic value and validate the Sentinel-MPE assay for accurately detecting cancer in pleural effusion samples, with the goal of bringing a new molecular diagnostic tool to the field of pathology. This work builds on prior feasibility and clinical utility data generated by Precision Epigenomics in collaboration with the University of Arizona.
Generated 3/4/25, 5:24 AM